Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer
Open Access
- 14 September 2019
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-10
Abstract
Background: Tumor-infiltrating immune cells are present in various malignant tumors, but their clinical significance in gastric cancer (GC) remains unclear. This study aimed to investigate the prognostic significance of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). Methods: Using a prospective database containing 401 cases of GC, we evaluated TIL (cluster of differentiation 8 (CD8) expression) and TAM (cluster of differentiation 68 (CD68) expression) statuses via immunohistochemical staining. Results: Compared with CD8+ TIL-negative cases (n = 196, 48.6%), CD8+ TIL-positive cases (n = 205, 51.1%) showed significantly better recurrence-free survival (RFS) [log-rank ppn = 217, 54.1%), CD68+ TAM-positive cases (n = 184, 45.9%) had significantly poor RFS [log-rank pp<0.001]. Thus, patients with a positive CD8+ TIL and negative CD68+ TAM status exhibited significantly increased RFS. Multivariate analysis demonstrated that CD8+ TILs and CD68+ TAMs may serve as independent prognostic markers for RFS. Incorporating CD8+ TIL and CD68+ TAM statuses into the AJCC TNM system generated a predictive model with better predictive accuracy for RFS. More importantly, patients with a positive TIL and negative TAM status showed a tendency of improved RFS after postoperative adjuvant chemotherapy (PAC). Similar results were obtained by overall survival (OS) analysis. Conclusions: CD8+ TIL and CD68+ TAM statuses were identified as independent prognostic factors that may be integrated into the current TNM staging system to refine risk stratification and to better predict the survival benefit from PAC in patients with GC. Trial registration: The current controlled trial was registered at ClinicalTrials.gov (ID: NCT02327481) on December 30, 2014.Keywords
Funding Information
- National Nature Science Foundation of China (No.81871899)
- Construction Project of Fujian Province Minimally Invasive Medical Center (No. [2017]171)
- The second batch of special support funds for Fujian Province innovation and entrepreneurship talents (2016B013)
- QIHANG funds of Fujian Medical University (No.2016QH025)
- Natural Science Foundation of Fujian Province (2019J01155)
This publication has 53 references indexed in Scilit:
- Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the LiteraturePLOS ONE, 2012
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- 7th Edition of the AJCC Cancer Staging Manual: StomachAnnals of Surgical Oncology, 2010
- Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancerBritish Journal of Cancer, 2008
- Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral FluoropyrimidineNew England Journal of Medicine, 2007
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Adjuvant Therapy in Gastric CancerJournal of Clinical Oncology, 2005
- The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinomaGastric Cancer, 2002